1258974-72-9Relevant academic research and scientific papers
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents
Cho, Wansang,Koo, Ja Young,Park, Yeonju,Oh, Keunhee,Lee, Sanghee,Song, Jin-Sook,Bae, Myung Ae,Lim, Donghyun,Lee, Dong-Sup,Park, Seung Bum
, p. 170 - 179 (2017/04/26)
Sepsis is one of the major causes of death worldwide when associated with multiple organ failure. However, there is a critical lack of adequate sepsis therapies because of its diverse patterns of pathogenesis. The pro-inflammatory cytokine cascade mediate
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand
Zhu, Mingyan,Kim, Myung Hee,Lee, Sanghee,Bae, Su Jung,Kim, Seong Hwan,Park, Seung Bum
supporting information; experimental part, p. 8760 - 8764 (2011/02/23)
A novel benzopyran-fused molecular framework 7ai was discovered as a specific inhibitor of RANKL-induced osteoclastogenesis using a cell-based TRAP activity assay from drug-like small-molecule libraries constructed by diversity-oriented synthesis. Its inhibitory activity was confirmed by in vitro evaluations including specific inhibition of RANKL-induced ERK phosphorylation and NF-κB transcriptional activation. 7ai can serve as a specific small-molecule modulator for mechanistic studies of RANKL-induced osteoclast differentiation as well as a potential lead for the development of antiresorptive drugs.
